Skip to main content
. 2019 Jul 1;86(2):251–263. doi: 10.1002/ana.25516

Figure 2.

Figure 2

Acetylated spermidine (Spd)/spermine (Spm) positively correlates with Parkinson disease severity. (A–F) Levels of N1,N8‐diacetylspermidine (DiAcSpd), N8‐acetylspermidine (N8‐AcSpd), and N1,N12‐diacetylspermine (DiAcSpm) positively correlated with Parkinson disease severity assessed by Hoehn and Yahr stages (H&Y), whereas other polyamine metabolites did not. Values indicate the amount of each metabolite (pmol) in 200μl serum. (G) Levels of Spm were significantly decreased in Parkinson disease, at H&Y stages I and IV. Values indicate the amount of each metabolite (pmol) in 200μl serum. (H) Receiver operating characteristic curves for all serum polyamine metabolites and corresponding area under the curve (AUC) statistics for the true positive rate of Parkinson disease diagnosis in Cohort B. (I) Scatterplots showing positive relationships between DiAcSpd and fractional anisotropy (FA) in Parkinson disease. (J) Significant positive correlation between N1,N8‐diacetylspermidine and FA, adjusted for age and L‐dopa equivalent dose (p < 0.05, familywise error corrected) in Parkinson disease patients. Significant clusters were overlaid onto a Montreal Neurological Institute (MNI) ICBM152 standard brain T1‐weighted image. Slices in MNI coordinates x, y, z are shown in millimeters. Colored bar represents p value. **p < 0.01, ***p < 0.001 (Steel test or analysis of variance). N1‐AcSpd = N1‐acetylspermidine; N1‐AcSpm: N1‐acetylspermine; NS = not significant.